Autism Pipeline Global Pharmaceutical Market Review For H1 2017

Autism Pipeline Review H1 2017 Pharmaceutical and Healthcare latest pipeline guide provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The report also reviews key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 3, 1, 15, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Complete report Thromboembolism Pipeline Review H1 2017 spread across 125 pages available at: http://www.rnrmarketresearch.com/Autism/report

With the list of tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Key Companies Discussed That Involved in Thromboembolism Therapeutics Development:

Addex Therapeutics Ltd,  Aequus Pharmaceuticals Inc, AgeneBio Inc, Anima Biotech Ltd, APeT Holding BV, Avanir Pharmaceuticals Inc, BioCrea GmbH, BioHealthonomics Inc, BrainStorm Cell Therapeutics Inc, Confluence Pharmaceuticals LLC, Coronis NeuroSciences Ltd, Curemark LLC, DRI Biosciences Corp, F. Hoffmann-La Roche Ltd, GW Pharmaceuticals Plc, Heptares Therapeutics Ltd, Immuron Ltd, Intra-Cellular Therapies Inc, Leading BioSciences Inc, MedDay SA, Omeros Corp, OptiNose US Inc, Sumitomo Chemical Co Ltd

Thromboembolism Drug Profiles Discussed In Report:

dextromethorphan + quinidine sulfate, acamprosate calcium, ACT-01, ADX-71441, ADX-88178, aripiprazole,CB-0306, CM-AT, CP-102, GWP-42006, histamine dihydrochloride, HTL-14242, IMM-124E, L-179, lumateperone tosylate, lurasidone hydrochloride, MD-1103, NurOwn, oxytocin, PAM-28,RG-7314, SF-999

Scope:

The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System). The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.  The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.  The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

Complete Report @: http://www.reportsnreports.com/autism-pipeline-review

Major Points from Table of Contents

  • Number of Products under Development for Autism, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Autism – Pipeline by Addex Therapeutics Ltd, H1 2017
  • Autism – Pipeline by Aequus Pharmaceuticals Inc, H1 2017
  • Autism – Pipeline by AgeneBio Inc, H1 2017
  • Autism – Pipeline by Anima Biotech Ltd, H1 2017
  • Autism – Pipeline by APeT Holding BV, H1 2017
  • Autism – Pipeline by Avanir Pharmaceuticals Inc, H1 2017
  • Autism – Pipeline by BioCrea GmbH, H1 2017
  • Autism – Pipeline by BioHealthonomics Inc, H1 2017
  • Autism – Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
  • Autism – Pipeline by Confluence Pharmaceuticals LLC, H1 2017
  • Autism – Pipeline by Coronis NeuroSciences Ltd, H1 2017
  • Autism – Pipeline by Curemark LLC, H1 2017
  • Autism – Pipeline by DRI Biosciences Corp, H1 2017
  • Autism – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Autism – Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Autism – Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Autism – Pipeline by Immuron Ltd, H1 2017
  • Autism – Pipeline by Intra-Cellular Therapies Inc, H1 2017
  • Autism – Pipeline by Leading BioSciences Inc, H1 2017
  • Autism – Discontinued Products, H1 2017

Get This Report at: http://www.rnrmarketresearch.com/Autism/reports

About Us:

Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

 

 

 

 

%d bloggers like this: